Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer  

作　　者：Yong Liu Hong-Gen Liu Cheng Zhao 

机构地区：[1]Department of Gastric Surgery,Tianjin Medical University Cancer Institute&Hospital,Tianjin 300000,China [2]Key Laboratory of Cancer Prevention and Therapy,National Clinical Research Center for Cancer,Tianjin 300000,China [3]Tianjin Key Laboratory of Digestive Cancer,Tianjin Clinical Research Center for Cancer,Tianjin 300000,China [4]Department of Oncology,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300000,China [5]National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion,Tianjin Cancer Institute of Traditional Chinese Medicine,Tianjin 300380,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期223-232,共10页世界胃肠肿瘤学杂志(英文)

基　　金：Supported by Scientific Research Project of Tianjin Municipal Education Commission,No.2018KJ015.

摘　　要：BACKGROUND Studies on the application of recombinant human endostatin(RH-endostatin)intraperitoneal perfusion in gastric cancer(GC)with malignant ascites are limited.AIM To explore the effectiveness,prognosis,and safety of intraperitoneal RH-endostatin perfusion in treating patients with GC and malignant ascites.METHODS Patients with GC and malignant ascites were divided into the cisplatin intraperi-toneal perfusion(control group)group and the cisplatin combined with RH-endostatin intraperitoneal perfusion group(RH-endostatin group).Efficient ascites control,overall survival(OS),quality of life,and adverse events were observed,and possible influencing factors on prognosis outcomes analyzed.RESULTS We identified no significant differences in baseline characteristics between the control and RH-endostatin groups.The latter group had higher ascites control rates than the control group.Treatment methods were identified as an independent OS factor.Clinically,RH-endostatin-treated patients had significantly improved OS rates when compared with control patients,particularly in those with small and moderate ascites volumes.Quality of life improvements in control patients were significantly lower when compared with RH-endostatin patients.Adverse events were balanced between the groups.CONCLUSION Overall,intraperitoneal RH-endostatin improved treatment efficacy and prolonged prognosis in patients with GC and malignant ascites.This approach may benefit further clinical applications for treating GC.

关 键 词：Gastric cancer Recombinant human endostatin Peritoneal metastasis Malignant ascites CISPLATIN Efficacy PROGNOSIS 

分 类 号：R73[医药卫生—肿瘤]